Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLOG: Atezolizumab with Carboplatin and Cyclophosphamide in Advanced Breast and Gynaecologic Cancer
NCT02914470Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2017
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in breast cancer, Cervical Cancer (CC), ovarian cancer and 1 more, sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of toxicity. Started Jan 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancerCervical Cancer (CC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT02914470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914470.